Clinical Neuropathology QUIZ #3

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Published in Clinical Neuropathology 39/5 (September/October 2020). Based on papers and editorial of the same issue. For your reference, here is the link to the table of content of issue 5: https://www.dustri.com/nc/journals-in-english/mag/clinical-neuropathology/vol/volume-39-2020/issue/septemberoctober-10.html

1. Within the Qualitative Assurance Initiative Pathology (QuIP) programme, which of the following tests has not yet been included in a round robin trial? *

1 point

a - IDH1-R132H Immunohistochemistry

b - TERT promoter mutation

c - MGMT promoter methylation

d - IDH1/2 mutation status

e - none of the above

2. Which of the following statements regarding CNS lymphoma is correct? *

1 point

a - They are usually located infratentorially

b - they occur most often in children and young adults

c - incidence rates have increased within the past decade

d - some cases are associated with an underlying autoimmune disorder

e - follicular lymphoma is fairly common in the CNS

3. Which of the following is the most common type of lymphoma on the CNS? *

1 point

a - diffuse large B-Cell lymphoma

b - high grade Lymphoma

c - mantle cell lymphoma

d - primary NK/T-cell lymphoma

e - post-transplant lymphoproliferative disorder

4. Which of the following characteristics distinguishes pulmonary barotrauma from decompression sickness? *

1 point

a - the localization of gas collections on radiographs

b - an injury to the pleural surfaces

c - signs of decomposition on external examination of the body

d - the diving history and equipment used

e - The localization/distribution of optically empty spaces on microscopic examination of the brain

5. In the case of Fahr's Disease co-occurring with dementia with Lewy Bodies, a mutation in which of the following genes was found? *

1 point

a - SCL20A2

b - PDGFB

c - APP

d - FUS

e - GRN

6. Which of the following entities has to be considered in the differential diagnosis of epithelial sheath neuroma? *

1 point

a - traumatic neuroma

b - squamous cell carcinoma

c -malignant neural neoplasm with heterologous elements

d - re-excision perineurial invasion

e - all of the above

7. For which of the following tumors copy number variation and somatic mutation burden have been shown to be of prognostic significance? *

1 point

a - astrocytomas WHO Grade II/III

b - medulloblastomas

c - ependymomas

d - CNS lymphomas

e - metastases

8. All of the following statements regarding copy number variation and somatic mutation burden in oligodendroglioma as described by Richardson et al are correct except: *

1 point

a - There is a significant correlation of total CNV with clinical outcomes

b - a cut-off for the distinction of good outcome versus poor outcome could be established

c - In an independent cohort of oligodendrogliomas, results were reproducible

d - somatic mutation burden is higher in cases with poor outcome

e - somatic mutation burden may be a useful prognostic marker in oligodendroglioma

9. Which of the following statements regarding aging related tau astrogliopathy is not correct *

1 point

a - it is a 3R-tauopathy

b - it occurs primarily in the elderly

c - ist incidence increases with age

d - there is no known association with clinical dementia

e - it is morphologically characterized characterized by thorny-shaped astrocytes and granular fuzzy astrocytes

10. All of the following statements regarding inclusion body myositis are correct except *

1 point

a - it belongs to the category of inflammatory myopathies

b - A PIB pet scan may serve to demonstrate the location of the disease process in vivo

c - The condition is associated with deposits af amyloid beta in muscle

d - Histologically, rimmed vacuoles are seen in affected muscle

e - most cases of inclusion body myositis are hereditary

Submit

Clear form

This form was created inside of Euro-CNS. Report Abuse

Forms